Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AgfiledCriticalBayer Schering Pharma Ag
Publication of CU20110036A7publicationCriticalpatent/CU20110036A7/en
Composiciones de administración de drogas en forma de películas delgadas solubles en agua (obleas), que contienen partículas que comprenden al menos una progestina y al menos un agente protector. El agente protector provee el enmascaramiento efectivo del sabor de la progestina debido a la liberación limitada de la progestina en la boca. Por consiguiente, la progestina no es absorbida a través de la ruta bucal, sino que lo es a través de la ruta entérica (peronal).Drug delivery compositions in the form of thin water-soluble films (wafers), which contain particles comprising at least one progestin and at least one protective agent. The protective agent provides effective masking of the taste of progestin due to the limited release of progestin in the mouth. Therefore, progestin is not absorbed through the buccal route, but is absorbed through the enteric (peronal) route.
CU20110036A2008-08-082011-02-08
DRUG ADMINISTRATION SYSTEM CONTAINING PROGESTINE
CU20110036A7
(en)
Rifaximin solid dispersion and a pharmaceutically acceptable carrier; pharmaceutical composition; use in the treatment and / or prevention of a microbial infection comprising the administration of the solid dispersion.